223 related articles for article (PubMed ID: 27282353)
1. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
2. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
Tian X; Xu J; Dorfman DM
Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
[TBL] [Abstract][Full Text] [Related]
3. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
Tian X; Xu J; Fletcher C; Hornick JL; Dorfman DM
Mod Pathol; 2018 Apr; 31(4):553-561. PubMed ID: 29327713
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
[TBL] [Abstract][Full Text] [Related]
5. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
6. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
[TBL] [Abstract][Full Text] [Related]
7. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
8. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
[TBL] [Abstract][Full Text] [Related]
10. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ
Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438
[TBL] [Abstract][Full Text] [Related]
11. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
[TBL] [Abstract][Full Text] [Related]
12. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
13. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
[TBL] [Abstract][Full Text] [Related]
14. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S
Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
Zhao X; Lwin T; Zhang X; Huang A; Wang J; Marquez VE; Chen-Kiang S; Dalton WS; Sotomayor E; Tao J
Leukemia; 2013 Dec; 27(12):2341-50. PubMed ID: 23538750
[TBL] [Abstract][Full Text] [Related]
16. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
17. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
18. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
[TBL] [Abstract][Full Text] [Related]
19. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.
Ryan RJ; Nitta M; Borger D; Zukerberg LR; Ferry JA; Harris NL; Iafrate AJ; Bernstein BE; Sohani AR; Le LP
PLoS One; 2011; 6(12):e28585. PubMed ID: 22194861
[TBL] [Abstract][Full Text] [Related]
20. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
